About
Bio
Impact factor:
Not presently indexed.
Journal ranking:
Not presently indexed.
Aims of the journal:
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 – 50% of adult patients with extrahepatic primary tumors.
Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy.
Content:
Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver
Clinical trials in hepatic oncology
Diagnosis and imaging
Epidemiology
Palliative care
Pathogenesis
Pathology
Pediatrics
Pharmacoeconomics, outcomes and comparative effectiveness research
Prognosis
Risk factors
Staging
Surveillance
Therapy, including surgery, chemotherapy, chemoembolisation, ablation, radiotherapy, hormonal and biological therapies
Translational research and biomarker studies
Other Information:
Average Lead Time to Online Publication: 14 - 16 weeks
Email
email@cision.one
Website
site@cision.one
Social media
Location
United Kingdom
Frequency
upgrade
Circulation
upgrade
Sectors
Oncology
Bio
Impact factor: Not presently indexed. Journal ranking: Not presently indexed. Aims of the journal: Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 – 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Content: Studies on all types of primary and secondary hepatic cancers, including hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, fibrolamellar carcinoma and mesenchymal cancers of the liver Clinical trials in hepatic oncology Diagnosis and imaging Epidemiology Palliative care Pathogenesis Pathology Pediatrics Pharmacoeconomics, outcomes and comparative effectiveness research Prognosis Risk factors Staging Surveillance Therapy, including surgery, chemotherapy, chemoembolisation, ablation, radiotherapy, hormonal and biological therapies Translational research and biomarker studies Other Information: Average Lead Time to Online Publication: 14 - 16 weeks
Website
Social media
Location
Frequency
Circulation
Sectors
Oncology
Most recent articles by Hepatic Oncology
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Article description
Explore outlets similar to Hepatic Oncology
-
OOncologyLive
Established in 2000 as Oncology Net Guide and rebranded in March 2011 as OncLive. Written for physicians to enable them to keep up to date with the rapidly expanding amount of medical information and resources on oncology. Designed as a handbook for frequent referencing and written in an easy-to-understand style. Articles are quick-reading, timely, provides practical information and information about new medical treatments. Media Alert: Tuesday April 12th 2011 Oncology Net Guide has changed its name to OncLive. Anita Shaffer is Associate Editor in charge of the oncology research and technology magazine. She may be reached at +1 (609) 716 7777 Ext 192 and ashaffer@onclive.com
ViewTTargeted OncologyTargeted Oncology is an online resource for oncology news and research, carrying content from Intellisphere's printed oncology journals, Targeted Therapies and The Journal of Targeted Therapies.
ViewMMedical News TodayBackground and Format: Launched in 2003, Medical News Today is a website overseen by Healthline Media UK Ltd and is aimed at healthcare professionals and consumers. Covers health news, diseases, nutrition & diet and pain & aesthetics. For more information about advertising rates, the team can be reached here. Circulation: Source: Publisher.
ViewAASH Clinical NewsASH Clinical News is a news publication from the American Society of Hematology and serves as a source for worldwide news and perspectives on hematology and oncology. Coverage includes blood disorders and related topics of interest to hematologists, including developments in oncology, endocrinology and cardiology. Each month it provides the latest updates in the field along with perspectives and opinions from key leaders as well as tools and resources to help clinicians with quality and performance improvement, patient education, and the economics of running a practice.
ViewTThe Lancet OncologyImpact Factor: 26.509 (Source:Thomson Reuters Journal Citation 2016) Format and Background: The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Circulation: The Publisher does not disclose the circulation. Aims of the journal: The Lancet Oncology was launched in September 2000 with the aim of being a lively and informative monthly journal covering international issues relevant to clinical cancer specialists worldwide. In May 2005, the journal expanded to include original research and began publishing articles online first prior to print publication. In 2008, the journal expanded its online presence to include regular podcasts. The aim of The Lancet Oncology is to publish interesting, informative, and practice-changing articles on any topic connected with clinical oncology. Readership: Clinical cancer specialists worldwide. Content: Topics include, but are not limited to: Breast cancer Endocrine system cancer Gastrointestinal cancer Genitourinary cancer Gynaecological cancer Haematological cancer Head and neck cancer Neurooncology Paediatric oncology Thoracic oncology Sarcoma Skin cancer Epidemiology, cancer prevention, and cancer control Supportive care Imaging Health-care systems Manuscript submission: The journal publishes a range of article types that encompass all aspects of oncological medicine: Comment, Correspondence, News, Cancer and Society, Article, Meta-analysis, Review, Historical Review, Health-care Development, Personal View, and Debate. For further information for authors, click here. Online manuscripts submission here. Ad Rates: Can be viewed here the advertising team can be reached at lancet-ads@elsevier.com Other Information: The RSS feed can be viewed here Podcasts can be found here Information for the press can be viewed here
ViewUse CisionOne to find more relevant outletsContact Hepatic Oncology and get access to over 850K accurate, up-to-date media profiles.
Discover the stories that impact your brand. In realtime.
CisionOne delivers relevant news, trends and conversations that matter to your brand with the world’s most comprehensive media monitoring service across Print, Online, TV, Radio, Social, Magazines, Podcasts and more.